Trial Profile

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jul 2023 Status changed from active, no longer recruiting to discontinued. Based on the adjustment of clinical research and development strategy, sponsor decided to terminate the study.
19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research
17 Apr 2023 According to an Antengene Corporation media release, data from this study were presented at the American Association for Cancer Research Annual Meeting 2023 Meetings (AACR 2023).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com